drugset / Trial / NCT06913725
An Exploratory Study to Evaluate the Efficacy and Safety of FCN-159 in Patients With Brain Arteriovenous Malformations
Phase 2
Recruiting
10 enrolled
Xuanwu Hospital, Beijing
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
A single-center, open-label, non-randomized controlled exploratory study is conducted in the Xuanwu Hospital Capital Medical University to evaluate the efficacy and safety of FCN-159 in patients with brain arteriovenous malformations (BAVM), aiming to overcome the current clinical challenges caused by the lack of available drugs for this disease.
Timeline
- Start
- 2025-02-24
- Primary completion
- 2026-03-31
- Completion
- 2026-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Luvometinib | Small molecule | 8 mg | Oral |